Eckert & Ziegler Finalizes Take Over Bid IBt
Change in the Management of IBt Bebig
At the closing of the acceptance period of the takeover bid on 17 March 2010, 6,042,144 IBt shares, all of the 25,000 IBt beneficiary shares B and 120,400 IBt warrants have been tendered in the takeover bid. As a result, Eckert & Ziegler now holds 12,635,594 IBt shares, 25,000 IBt beneficiary shares B and 120,400 IBt warrants, or 56% of IBt’s voting rights. SMI holds 5,000,000 IBt beneficiary shares A, or 22 % of IBt’s voting rights. As announced in their transparency declaration of 6 January 2010, Eckert & Ziegler and SMI are acting in concert in the framework of the takeover bid.
Payment of the consideration for the IBt shares, IBt beneficiary shares B and IBt warrants shall be made by the receiving and paying agent KBC Securities, on 7 April 2010, directly to the beneficiaries or via their financial institution.
IBt Bebig also announced today that the CEO, Mr François Blondel, and the Company have decided to end their collaboration. As a result, Mr François Blondel will resign, with immediate effect, from all of his duties and responsibilities within the Group, whether as a Director of IBt s.a. or of its subsidiaries.
Dr. Edgar Löffler and Dr. Gunnar Mann, directors of IBt, have been appointed as the new persons in charge of the daily management of the company. They will take over the responsibilities of Mr. Blondel and manage IBt jointly, each in his capacity as Managing Director.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
